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were mainly (>75%) HCV-associated [4], and the risk factor was
different from that of our samples. For the 19 HCC samples used
by Connolly et al., nine were HBsAg positive but the HBV status
was not available in the remaining 10 cases. In addition, these
HCC samples were collected from Qidong area of Jiangsu Province
of China, where aﬂatoxin B1 is a common risk factor of HCC [2].
The diversity of the etiological background of the samples,
together with the various experimental approaches involved,
very much hinders direct comparison of data among the different
studies. For this reason, experimentally uniﬁed and well con-
trolled studies on large sample cohorts are required to investigate
the effects of different etiological factors on miRNA deregulation
in human HCCs.
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Is a liver biopsy necessary in alcoholic hepatitis?
To the Editor: patients with ALD presenting with Acute-on-Chronic Liver Failure
(ACLF) which has recent onset of hyperbilirubinaemia (>85 lmol/
L) as a major tenant of its deﬁnition [7]. In this group of patients
again, 96% had features of ASH. In the paper by Mookerjee, the
criteria for a clinical diagnosis of ASH appear to have been
decompensated ALD with the presence of SIRS without a mini-
mum value of bilirubin stipulated. ‘‘Progressive jaundice’’ was
just one of three criteria used to deﬁne the patient group studied.
Furthermore, no information was provided regarding duration of
liver disease at time of biopsy. Previous experience indicates that
the accuracy of clinical diagnosis of alcoholic hepatitis is highest
if the biopsy is performed within 4 weeks of initial presentation
[8].
Whilst Maddrey’s Discriminant Function (DF) has been a land-
mark advance in the assessment of alcoholic hepatitis, its accu-
racy is in question not least of all because it relies upon the
measured prolongation of the prothrombin time, which is prone
to signiﬁcant laboratory variation. Additionally, in the paper by
Mookerjee, the DF was not found to be predictive of 28-day out-
come. More recently, the MELD score and the Glasgow Alcoholic
Hepatitis Score (GAHS) have been shown to identify poor out-
come from alcoholic hepatitis [2,9]. These have similar AUC val-
ues to those described for the histological ASH grade described
in the paper by Mookerjee et al. The paper did not demonstrate
that their histological data were independently predictive of sur-
vival or added signiﬁcantly to the predictive value of these scores.
The development of a reproducible histological score for alcoholic
hepatitis is to be applauded. However, even in this specialist cen-
tre there was a delay of up to 7 days before the biopsies were
obtained. With the additional time for preparation and interpre-
tation of the specimens, the delay in obtaining a prognosis from
histological criteria is signiﬁcant and the opportunity to inter-
vene early in those patients who may beneﬁt may be lost. How-
ever, clinical scores such as the GAHS, readily calculable on the
day of admission and over subsequent days, are not only accurate
JOURNAL OF HEPATOLOGYThe paper by Mookerjee et al. allowed a fascinating insight into
the prognostic relevance of the systemic inﬂammatory response
(SIRS) in decompensated alcoholic liver disease (ALD), especially
the presence of alcoholic steatohepatitis (ASH) [1]. However, the
paper makes some assertions which require further discussion.
The main assertion is that a liver biopsy is essential to deter-
mine the diagnosis and prognosis in patients with ASH. Not only
is this contrary to recently published guidelines [2], there are
practical issues in obtaining and interpreting transjugular liver
biopsies. Few liver centres in the United Kingdom can readily
provide such a service. In 2009/10 there were 14,700 hospital
admissions in England alone for alcoholic liver disease: 5700 with
‘‘alcoholic cirrhosis’’ and 1600 with ‘‘alcoholic hepatitis’’ [3].
Mookerjee et al. describe biopsies in 71 patients over a 3-year
period. The provision of transjugular liver biopsies throughout
the rest of the United Kingdom and Europe for the thousands of
additional ALD patients is unrealistic. A management strategy
based upon an impractical level of investigation will not beneﬁt
most patients with ALD. We must ensure that we can assess
and effectively manage these patients in all hospitals and not
solely in limited specialist centres.
With regards to the need for biopsy for diagnosis of alcoholic
hepatitis, the ﬁgure of 70–80% accuracy of a clinical diagnosis
subsequently conﬁrmed by biopsy is often quoted [2]. However,
the most consistent difference between patients with alcoholic
hepatitis and other patients with decompensated ALD is the
degree of hyperbilirubinaemia [4,5]. A recent review of all the
randomised controlled trials of treatments for alcoholic hepatitis
determined the accuracy of the clinical criteria used relative to
subsequent histological conﬁrmation. If only those studies, which
used a minimum level of bilirubin (ranging from 80 to 100 lmol/
L) or whose patient population had a lower limit of bilirubin
greater than 80 lmol/L, were considered, the accuracy of a clini-
cal diagnosis rose to 96% [6]. This is very similar to a group ofJournal of Hepatology 2012 vol. 56 j 1420–1429 1427
from a prognostic point of view but also appear to be able to
identify those patients likely to beneﬁt from therapeutic inter-
vention [9,10]. The prognostic utility of the presence of SIRS cri-
teria has previously been described in ALD patients with ACLF [7].
This may in part explain the prognostic accuracy of the GAHS as
white cell count is a principle component of both SIRS and GAHS.
In conclusion, it is unrealistic to suggest that biopsy is essen-
tial for the diagnosis and prognosis of patients with alcoholic
hepatitis. Whilst biopsy may be necessary in cases of diagnostic
uncertainty and for the characterisation of patients for research
purposes, clinical criteria for diagnosis and identiﬁcation of
patients for treatment are readily available for the majority of
patients with alcoholic hepatitis. The aim should be to assess
such patients promptly on presentation rather than to rely upon
strategies based upon histology which may delay assessment or
be difﬁcult to obtain outside specialist centres.
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Reply to: ‘‘Is a liver biopsy necessary in alcoholic hepatitis?’’
To the Editor:
We thank Drs. Forrest and Gleeson for their interest in our paper
[1]. Their letter makes two points; one clinical and the other
logistical, which will be addressed in turn.
Clinical
Our study describes the value of early liver biopsy (between
days 1 and 7 from admission) in patients presenting with acute
decompensation of cirrhosis. As correctly identiﬁed by Forrest
and Gleeson, only biopsies taken early in the admission are valu-
able in interpreting the cause of decompensation. However, we
beg to differ with them on the relative importance placed on
hyperbilirubinaemia as a key feature of ASH versus other causes
of decompensated alcoholic liver disease. Indeed, in the paper
they cite by Katoonizadeh et al. [2], patients with acute-on-
chronic liver failure (ACLF) presenting with hyperbilirubinaemia
had most commonly sepsis with high SIRS, conﬁrmed by ductu-
lar bilirubinostasis, which was also an independent prognostic
factor. In our series, mean bilirubin values of 227 lmol/L in
heavy drinkers with onset of jaundice less than 1 month from
the acute admission ﬁts with other studies addressing diagnos-
tic criteria in ASH [3,4]. However, 50% of patients with high SIRS
had no signiﬁcant histological features of ASH using the grading
system we describe and yet sepsis related mortality was higher
in these patients with their biopsies showing signiﬁcant
cholestasis. Thus, high bilirubin cannot distinguish infection
from the hepatic inﬂammation of ASH in decompensated
cirrhosis and their respective management is completely
different.
Louvet et al. show that in patients failing corticosteroid treat-
ment of ASH, mortality from infection is high, suggesting that cor-
ticosteroidsmay promote increased infection in these patients and
precipitate poor outcome [5]. It follows that the practice of clinical
grading of AH in a decompensated alcoholic cirrhotic is likely to
signiﬁcantlyunderestimate infection, adversely impact on survival
and inappropriately target anti-inﬂammatory therapies fromthose
patients inmost need, i.e. thosewith severe histological ASH. Thus,
whilst desirable to make a rapid diagnosis of ASH to institute
appropriate therapy, to commence therapy on clinical grounds
may be more hazardous to the patient than availing objective
biopsy conﬁrmation. Additionally,mostof the largeFrenchcortico-
steroid trials includedpatients after a liver biopsy to diagnoseASH.
Therefore, to suggest use of corticosteroids without liver biopsy
conﬁrmation is not based on evidence.
In relation to use of widely published scoring systems such as
modiﬁed DF, MELD and more recently GAHS [6,7], we agree that
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